Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Substance (drug) abuse – pipeline review, h2 2012


Published on

2012 || Oncology || Substance (Drug) Abuse – Pipeline Review, H2 2012 ||

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

Substance (drug) abuse – pipeline review, h2 2012

  1. 1. announces, The Latest market research report is available inits vast collection:Substance (Drug) Abuse – Pipeline Review, H2 2012 link of Global Markets Direct Markets Direct’s, Substance (Drug) Abuse - Pipeline Review, H2 2012,provides an overview of the Substance (Drug) Abuse therapeutic pipeline. Thisreport provides information on the therapeutic development for Substance (Drug)Abuse, complete with latest updates, and special features on late-stage anddiscontinued projects. It also reviews key players involved in the therapeuticdevelopment for Substance (Drug) Abuse. Substance (Drug) Abuse - PipelineReview, H2 2012 is built using data and information sourced from Global MarketsDirect’s proprietary databases, Company/University websites, SEC filings, investorpresentations and featured press releases from company/university sites andindustry-specific third party sources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Substance (Drug) Abuse.- A review of the Substance (Drug) Abuse products under development bycompanies and universities/research institutes based on information derived fromcompany and industry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.
  2. 2. - A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.Table of contents:List of Tables 6List of Figures 7Introduction 8Global Markets Direct Report Coverage 8Substance (Drug) Abuse Overview 9Therapeutics Development 10An Overview of Pipeline Products for Substance (Drug) Abuse 10Substance (Drug) Abuse Therapeutics under Development by Companies 12Substance (Drug) Abuse Therapeutics under Investigation by Universities/Institutes13Late Stage Products 16Comparative Analysis 16Mid Clinical Stage Products 17Comparative Analysis 17Early Clinical Stage Products 18Comparative Analysis 18Discovery and Pre-Clinical Stage Products 19Comparative Analysis 19Substance (Drug) Abuse Therapeutics – Products under Development by Companies20Substance (Drug) Abuse Therapeutics – Products under Investigation byUniversities/Institutes 21Companies Involved in Substance (Drug) Abuse Therapeutics Development 27Snowdon Inc. 27Dr. Falk Pharma GmbH 28Celtic Pharmaceutical Holdings L.P. 29Substance (Drug) Abuse – Therapeutics Assessment 30Assessment by Monotherapy Products 30Assessment by Combination Products 31Assessment by Route of Administration 32Assessment by Molecule Type 34Drug Profiles 36
  3. 3. CR 2249 - Drug Profile 36Lofexidine + Marinol - Drug Profile 37Tenex - Drug Profile 38List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012 Review, H22012&PubId=&pagenum=1Brain Tumor – Pipeline Review, H2 2012Colon Cancer – Pipeline Review, H2 2012Hodgkin Lymphoma – Pipeline Review, H2 2012Substance (Drug) Abuse – Pipeline Review, H2 2012Metastatic Pancreatic Cancer – Pipeline Review, H2 2012Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H2 2012B-Cell Leukemia – Pipeline Review, H2 2012Malignant Neoplasms – Pipeline Review, H2 2012
  4. 4. Recurrent Malignant Glioma – Pipeline Review, H2 2012Endobronchial Cancer – Pipeline Review, H2 2012Leiomyosarcoma – Pipeline Review, H2 2012Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2012Esophageal Tumor – Pipeline Review, H2 2012Malignant Pleural Mesothelioma – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcare andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: